MetaCurUm Biotech has won an innovation competition announced by Groth & Co.
MetaCurUm Biotech develops a new treatment of aggressive cancer. The company is a spin-off from Umeå University and was founded by Professor Maréne Landström. MetaCurUm Biotech is a resident at Umeå Biotech Incubator. The company has now been named one of two winners of an innovation competition and will receive a prize consisting of an IPR consultation worth SEK 75,000.
The competition was announced by Groth & Co in conjunction with their 150th anniversary, where Swedish innovation companies were invited to compete for a price worth SEK 150,000. Among many impressive and innovative companies, the jury was able to agree on two worthy winners, MetaCurUm Biotech and Mycorena, who will split the prize money and thus receive counseling for SEK 75,000 each.
Focus on prostate cancer
MetaCurUm Biotech’s main focus is on prostate cancer, which is the most common form of cancer among men in Sweden, but there are indications that the treatment may also be relevant in other types of cancer.
”Our long term goal is to provide patients suffering from aggressive cancer with a new treatment option. We are currently working on showing that the treatment works in a cancer model. At the same time, we aim to raise money so that we can finance our continued development,” says Lotta Berg, CEO of MetaCurUm Biotech. ”To receive a consultation worth SEK 75,000 really makes a difference in the phase that the company is in right now, and it is a very valuable help to receive.”
Photo of Lotta Berg: Metacurum